First patients receive experimental pill targeting Hard-to-Treat cancers
NCT ID NCT07284186
Summary
This is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGScottsdale, Arizona, 85258, United States
-
Research Site
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Research Site
NOT_YET_RECRUITINGOrange, California, 92868, United States
-
Research Site
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
Research Site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Site
NOT_YET_RECRUITINGNew York, New York, 10044, United States
-
Research Site
RECRUITINGDurham, North Carolina, 27710, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.